Log In
BCIQ
Print this Print this
 

HRAS and survivin UsiRNA formulated in a single DiLA2 lipid-based delivery vehicle

  Manage Alerts
Collapse Summary General Information
Company Marina Biotech Inc.
DescriptionDuplex short interfering RNAs (siRNAs) modified with unlocked nucleobase analogs (UNA) formulated in a DiLA2 liposome formulation targeting HRAS and survivin
Molecular Target v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) ; Survivin (BIRC5)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationBladder cancer
Indication DetailsTreat bladder cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$11.1M

$1.0M

0


 Deals Details
Get a free BioCentury trial today